ClinicalTrials.gg
TerminatedNCT05695391SCOPE HIMUpdated Jul 31, 2026Results posted

Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery

A Phase 3 interventional study of Coagulation Factor VIIa (Recombinant) in Hemophilia, sponsored by Laboratoire français de Fractionnement et de Biotechnologies. Terminated at 15 sites in 6 countries. Open to male participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Laboratoire français de Fractionnement et de Biotechnologies · Phase 3, Interventional, and Treatment

Why this study was terminated
Feasibility considerations - extended timelines to complete recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing recombinant FVIIa in Hemophilia A — 1 open to participants now, 1 under way, none of them phase 3. recombinant FVIIa · Hemophilia A.

Enrollment
18th of 19
2 · median 24
Started
2024
the only one that year
Phase 3
5 of 20
none open now
Registered
20th of 20
by date
Lead sponsor
2 of 20
Laboratoire français de Fractionnement et de Biotechnologies

Among the 20 studies testing recombinant FVIIa in Hemophilia A, this one is the 18th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2024, is one of 5 in phase 3, and was the 20th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 20 studies testing recombinant FVIIa in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About recombinant FVIIa

recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing recombinant FVIIa in Hemophilia A, or all of them as a file.
02

Study summary

This is an interventional, prospective, international, multicenter, single-arm, Phase 3, and sequential efficacy and safety study in adolescents and adults with congenital hemophilia A or B with inhibitors to factor VIII (FVIII) or factor IX (FIX) undergoing elective major surgical procedures.

03

Conditions studied

  • Hemophilia

Browse trials for

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each patient must meet the following criteria to be enrolled in this study:

  1. be male with a diagnosis of congenital hemophilia A or B of any severity
  2. have one of the following:

    1. current positive inhibitor test BU ≥5 (as confirmed at screening by the institutional lab) or history of high-responding inhibitors (BU ≥5) not further successfully treated by Immune Tolerance Induction OR
    2. a condition precluding the use of FVIII or FIX products to treat or prevent bleeding such as a previous anamnestic response after exposure to factor concentrates or a previous failure to respond to FVIII or FIX concentrates
  3. be ≥12 years to ≤65 years of age on the day of
  4. be scheduled for an elective major surgical procedure as defined in the study protocol (see Table ''Definitions for the specific purpose of Study F7TG2202'')
  5. have ≥ 12 g/dL
  6. be capable of understanding and willing to comply with the conditions of the protocol OR in the case of a patient under the age of legal majority, parent(s)/legal guardian(s) must be capable of understanding and willing to comply with the conditions of the protocol
  7. have read, understood, and provided written informed consent (patient or parent(s)/legal guardian(s) if the patient is minor according to local regulation) and, where applicable according to local regulation, patient's assent if the patient is minor

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study.

  1. have any coagulation disorder other than hemophilia A or B
  2. be (i.e. the patient should not be receiving systemic immunosuppressive medication; at screening should be >200/μL)
  3. known intolerance to EB or any of its
  4. currently receiving immune tolerance induction (ITI) therapy
  5. have a known or suspected allergy or to rabbits or rabbit proteins
  6. have count \<100,000/μL
  7. have received an drug within 30 days or within 5 half-lives of that investigational drug, whichever is longer, of the planned first EB administration, or be expected to receive such drug during participation in this study. Patients who have received fitusiran in a clinical study may not participate in this clinical study for 6 months since the last dose and if they have an antithrombin III level not in the normal range at screening.
  8. for patients using emicizumab, have received during the last 6 months or currently receiving a maintenance dosing regimen of emicizumab different from the indicated one ± 10% of approved dose), i.e. different from 1.5 mg/kg once weekly (±10%), 3 mg/kg (±10%) every two weeks or 6 mg/kg (±10%) every four weeks
  9. for patients using emicizumab, currently be any plans, or notes in the patient's medical records that would suggest the need to increase or decrease emicizumab dosing due to antidrug antibodies (ADAs), reduced PK, or coagulation/safety-related issues (e.g. lack of response, or potential/actual thromboembolic concerns, etc)
  10. have a hepatic ( [AST] and/or alanine aminotransferase [ALT] >3 times the [ULN]) and/or renal impairment (creatinine >2 times the ULN)
  11. have a history of arterial and/or venous thromboembolic events (such as myocardial infarction, ischemic strokes, , DVT, or PE) within 2 years prior to the planned first dose of LR769, uncontrolled arrhythmia, or current (NYHA) functional classification score of stages II - IV
  12. have an active (those with non-melanoma skin cancer are allowed)
  13. have any life-threatening disease or other disease or condition which, according to the investigator's judgment, could imply a potential hazard to the patient, or interfere with the study participation or study outcome (e.g. chronic, unmanaged hepatitis infection)
  14. be using aspirin, non-steroidal anti-inflammatory drugs (NSAIDS), herbs, natural medications, or other drugs with platelet inhibitory properties within one week prior to surgery and for the duration of treatment with EB
  15. have active gastric or duodenal ulcer disease
  16. have received a FVII- or FVIIa-containing product (either plasma derived or recombinant) within 24 hours prior to administration of EB
  17. have a to antifibrinolytics
  18. have planned combined major surgeries at the same time or have already been enrolled and treated for a previous elective major surgery in the same SCOPE HIM study
  19. be administered pharmacologic thromboprophylaxis within 5 half-lives of that medication before surgery or for the duration of treatment with EB -
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Coagulation Factor VIIa (Recombinant)

    Biological: Coagulation Factor VIIa (Recombinant)

Interventions

06

What researchers measure

Primary outcomes

  1. Eptacog Beta (Activated) (EB) Effectiveness Based on Protocol's Aggregate Score

    Successfully treated major procedures defined by a good or excellent global hemostatic response, based on an aggregate score from 3 timepoints (intra-operative, 24h post-operative, 120h post-operative), each individual score depending on comparison between actual and preliminary-communicated expected blood loss and transfusions for a similar patient without bleeding disorder undergoing the same surgical procedure, but also on the use or not of IMP extra-doses or of rescue therapy.

    Time frame: From surgical wound closure until 120 hours after surgical wound closure

07

Results

Posted Jul 31, 2026
Limitations and caveats
The study was prematurely discontinued due to persistent difficulties in recruiting patients.There was no safety issue or concern. As the study was terminated early, no conclusions can be drawn from this study regarding the efficacy of Eptacog Beta (activated).

Participant flow

Male patients, aged ≥12 years to ≤65 years, with hemophilia A or B with positive inhibitor test BU ≥5 (current or past if not further successfully treated by ITI), or a condition precluding the use of FVIII or FIX products to treat/prevent bleeding, and scheduled to undergo an elective major surgery, were to be enrolled. Major surgeries were those that usually required ≥5 days of factor replacement in this population and typically involved entry into a body cavity or similarly complex procedures

Participant flow — Overall Study
MilestoneCoagulation Factor VIIa (Recombinant)
Started2
Completed2
Not completed0

Outcome measures

PrimaryEptacog Beta (Activated) (EB) Effectiveness Based on Protocol's Aggregate Score

Successfully treated major procedures defined by a good or excellent global hemostatic response, based on an aggregate score from 3 timepoints (intra-operative, 24h post-operative, 120h post-operative), each individual score depending on comparison between actual and preliminary-communicated expected blood loss and transfusions for a similar patient without bleeding disorder undergoing the same surgical procedure, but also on the use or not of IMP extra-doses or of rescue therapy.

Time frame:
From surgical wound closure until 120 hours after surgical wound closure
Reported as:
Count of participants · Participants
Eptacog Beta (Activated) (EB) Effectiveness Based on Protocol's Aggregate Score
ParticipantsCoagulation Factor VIIa (Recombinant)
Excellent or good rating1
Moderate or poor rating1
Post-hocEptacog Beta (Activated) (EB) Effectiveness Based on Data Monitoring Committee Review

Hemostatic response assessed by independent Data Monitoring Committee based on actual bleeding data and surgery types

Time frame:
From surgical wound closure until 120 hours after surgical wound closure
Reported as:
Count of participants · Participants
Eptacog Beta (Activated) (EB) Effectiveness Based on Data Monitoring Committee Review
ParticipantsCoagulation Factor VIIa (Recombinant)
Excellent or good response2
Moderate or poor response0

Adverse events

Collected over Adverse Events (AEs) were to be collected from the time of signing of the informed consent/assent until resolution or until the follow-up call which was 30 ± 2 days after the last dose of EB, or until early termination, whichever came first. As only 2 patients were effectively enrolled in the study, any AE would have a frequency of at least 50%, thus effectively exceeding the frequency threshold above which other adverse events are reported, therefore all AEs are reported.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Coagulation Factor VIIa (Recombinant)0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent other events
Most frequent other events
EventCoagulation Factor VIIa (Recombinant)
Sinus tachycardiaCardiac disorders1/2
Oral herpesInfections and infestations1/2
Incision site painInjury, poisoning and procedural complications1/2
Post procedural inflammationInjury, poisoning and procedural complications1/2
Procedural painInjury, poisoning and procedural complications1/2
Unintentional medical device removalInjury, poisoning and procedural complications1/2
HyperglycaemiaMetabolism and nutrition disorders1/2
AnxietyPsychiatric disorders1/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Coagulation Factor VIIa (Recombinant)
<=18 years0
Between 18 and 65 years2
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Coagulation Factor VIIa (Recombinant)
Female0
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Coagulation Factor VIIa (Recombinant)
Hispanic or Latino1
Not Hispanic or Latino1
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Coagulation Factor VIIa (Recombinant)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White1
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Coagulation Factor VIIa (Recombinant)
United States1
South Africa1
08

Study locations

15 sites
  • Orthopaedic Institute for Children - Orthopaedic Hemophilia Treatment Center
    Los Angeles, California 90007, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
  • Tulane Univertsity School of Medecine
    New Orleans, Louisiana 70112, United States
  • M Health Fairview Center for bleeding and Clotting disorders
    Minneapolis, Minnesota 55455, United States
  • University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Hospital Queen Elisabeth - Kota Kinabalu
    Kota Kinabalu, Sabah Province 88586, Malaysia
  • Hospital Ampang
    Ampang, Selangor Province 68000, Malaysia
  • Hospital Universitario Dr. José Eleuterio González de Nuevo León
    Monterrey, Nuevo León 64460, Mexico
  • Charlotte Maxeke Johannesburg Academic Hospital
    Johannesburg, Gauteng 2196, South Africa
  • Chiang Mai University
    Chiang Mai, 50200, Thailand
  • Maharaj Nakorn Chiangmai Hospital, Chiangmai University
    Chiang Mai, 50200, Thailand
  • Acibadem Adana Hospital
    Seyhan, Adana 01130, Turkey (Türkiye)
  • Hacettepe Üniversitesi Rektörlüğü Sihhiye
    Altındağ, Ankara 06230, Turkey (Türkiye)
  • Istanbul Üniversitesi Onkoloji Enstitusu
    Fatih, Istanbul 34093, Turkey (Türkiye)
  • Karadeniz Teknik Üniversitesi
    Trabzon, Trabzon 61080, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in May 2025, 11 months.

Results were first posted in Jul 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2022
First posted
Jan 25, 2023
StartActual
Jun 7, 2024
Primary completionActual
May 28, 2025
CompletionActual
Jul 7, 2025
Results first posted
Jul 31, 2026
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05695391
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Responsible party
Sponsor
First posted
Jan 25, 2023
Start date
Jun 7, 2024
Primary completion
May 28, 2025
Completion
Jul 7, 2025
Results posted
Jul 31, 2026
Last update
Jul 31, 2026

Study contacts

Miguel ESCOBAR, MD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion